A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs PF 6823859 (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Jan 2018 Status changed from not yet recruiting to recruiting.
- 11 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 15 Jan 2018.
- 07 Nov 2017 Planned initiation date changed from 20 Oct 2017 to 30 Nov 2017.